LUPROVA 22.5MG INJECTION

LUPROVA 22.5MG INJECTION works by suppressing the production of certain hormones, thereby reducing symptoms associated with conditions like prostate cancer, endometriosis, and uterine fibroids.

LUPROVA 22.5MG INJECTION is a GnRH agonist that acts on the pituitary gland, leading to the suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release. By desensitizing the GnRH receptors, LUPROVA 22.5MG INJECTION inhibits the production of sex hormones, such as <TESTOSTERONE> in males and estrogen in females. In prostate cancer, it causes a decrease in <TESTOSTERONE> levels, which helps to slow the growth and spread of cancer cells. In conditions like endometriosis, LUPROVA 22.5MG INJECTION reduces estrogen levels, resulting in the suppression of the endometrial tissue's growth and relieving associated symptoms. For uterine fibroids, LUPROVA 22.5MG INJECTION creates a state of medical menopause, reducing estrogen levels and shrinking the fibroids. In cases of precocious puberty, it temporarily halts the early onset of puberty by inhibiting the release of LH and FSH. The precise dosage and duration of treatment vary depending on the specific condition being treated.